Agios Pharmaceuticals, Inc. (AGIO) financial statements and ratios from SEC XBRL: revenue $0.1B (TTM), net margin -764.0%, revenue growth 48.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $54.03M |
| Revenue (TTM) | $0.1B |
| Net Margin | -764.0% |
| Operating Margin (TTM) | -419.0% |
| Revenue Growth (YoY) | 48.0% |
| EPS Growth (YoY) | -160.0% |
| FCF Growth (YoY) | -3.6% |
| Price / Book | 1.92 |
| Price / Sales | 19.86 |
| FCF Yield | -35.4% |
| Altman Z-Score | 10.21 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
AGIO overview · AGIO earnings · AGIO KPIs · AGIO documents · AGIO ownership · AGIO peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.